Form 4: BioXcel CFO Granted 9,000 Restricted Stock Units

BioXcel Therapeutics' Chief Financial Officer, Richard I. Steinhart, received a grant of 9,000 Restricted Stock Units.

Summary

• Richard I. Steinhart, Chief Financial Officer of BioXcel Therapeutics, Inc. (BTAI), was granted 9,000 Restricted Stock Units (RSUs).
• The grant date for these RSUs was August 1, 2025.
• Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
• The RSUs will vest 100% on or within 30 days of 9 months from the Grant Date, subject to Mr. Steinhart's continued employment with the Issuer or a subsidiary.

Sentiment

Score: 6

Explanation: A standard RSU grant to a key executive is generally a neutral to slightly positive event, indicating management retention and alignment of interests, but it does not reflect operational or financial performance.

Positives

• The grant of Restricted Stock Units aligns the Chief Financial Officer's interests with long-term shareholder value.
• It serves as a retention mechanism for key management personnel.

Negatives

• Potential for minor dilution if the RSUs convert to common stock upon vesting, though 9,000 shares is a relatively small amount.

Risks

• The vesting of RSUs is contingent on continued employment, meaning the benefit is lost if employment ceases before the vesting date.

Future Outlook

The grant of Restricted Stock Units with a future vesting date indicates an expectation of continued employment for the Chief Financial Officer and aligns his incentives with the company's long-term performance.

Industry Context

This filing is a standard disclosure of executive compensation, common across all industries for publicly traded companies, and does not provide specific industry-related insights.

Stakeholder Impact

• Shareholders: Potential for minor dilution upon vesting, but also improved alignment of the CFO's interests with shareholder value.
• Employees: May signal stability in executive leadership.

Next Steps

• Vesting of the 9,000 Restricted Stock Units on or within 30 days of 9 months from the August 1, 2025 grant date, subject to continued employment.

Key Dates

Keywords

BioXcel Therapeutics, BTAI, Restricted Stock Units, RSU, Executive Compensation, Insider Transaction, Form 4, Richard I. Steinhart, CFO